Sydney biosensor specialist Ambri (ASX:ABI) appeared to hit a setback last week, when the company announced that its US partner would no longer work to develop Ambri's ion-channel switch (ICS).

Biosensor Enterprises (BEL) will no longer work to develop Sydney-based Ambri's (ASX:ABI) ion-channel switch (ICS), and will instead focus on out-licensing the technology.

Sydney biosensor developer Ambri (ASX:ABI) has decided to bypass 'Go' with its SensiDx point-of-care biochip system, and fast-track second-generation chip capable of performing up to six different antibody tests simultaneously.

Listed biotech Ambri Ltd has laid off 15 staff in response to unexpected manufacturing problems in scaling up its biosensor technology for commercial production.

Biosensor company Ambri will receive an injection of up to $15.7 million under an equity and technology licensing pact with Dow Corning Corp and diversified US biotech Genencor International.